JayChristopherAndersenMD

Oncology • Portland, OR

Physician

Join to view full profile

Dr. Andersen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Andersen's full profile

Already have an account?

Office
9555 SW Barnes Rd
Ste 150
Portland, OR 97225
Phone+1 503-297-7403

Fax+1 503-384-9908

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2002
University of Kansas School of MedicineResidency, Internal Medicine, 1996 - 1999
University of Kansas School of MedicineClass of 1996

Certifications & Licensure

WA State Medical License 2004 - 2026
OR State Medical License 2004 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care...
Heather L McArthur, Sara M Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah
Therapeutic Advances in Medical Oncology. 2025-01-01
5 citations
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen
Breast Cancer. 2024-09-01
13 citations
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Joanne L Blum
The Oncologist. 2023-10-03

Press Mentions

Preparing for a Baby After Cancer - US NewsJune 19th, 2015

Professional Memberships

American Society of Clinical Oncology - ASCO
Member